Drug Profile
Research programme: Central nervous system disorder therapies - Dong Wha Pharmaceutical
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Dong Wha Pharmaceutical
- Developer Dong Wha Pharmaceutical; Handong Global University
- Class
- Mechanism of Action Dopamine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schizophrenia; Stroke
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Schizophrenia in South Korea
- 16 Jul 2016 No recent reports of development identified for research development in Stroke in South Korea
- 03 Nov 2009 Early research in Schizophrenia in South Korea (unspecified route)